Skip to contentC
CV Sciences, Inc.
C
CVSICV Sciences, Inc. Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$5.20M$5.20Mderived−44.3% vs Q4 2019 Net Income-$9.29M-$9.29MderivedN/M vs Q4 2019 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CV Sciences, Inc. · CIK 1510964 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$2,221,000−46.5% Operating Incomederived-$9,464,000N/M Operating Cash Flowderived-$1,468,000N/M Free Cash Flowderived-$1,731,000N/M Margins · derivedGross margin42.7%−1.8 pt vs Q4 2019
Operating margin-182.0%−103.3 pt vs Q4 2019
Net margin-178.8%−107.1 pt vs Q4 2019
ended Dec 31, 2020 · filed Mar 19, 2021 · 78 d after period end